MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

23.53 1.69

Buy Sell

Overview

Share price change

24h

Current

Min

22.99

Max

23.76

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+48.17% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	200M 2.4B
Previous open	21.84
Previous close	23.53

News Sentiment

By Acuity

42%

58%

146 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 kwi 2026, 17:13 UTC

Major Market Movers

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 kwi 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 kwi 2026, 23:35 UTC

Market Talk

Major News Events

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 kwi 2026, 22:41 UTC

Earnings

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 kwi 2026, 22:38 UTC

Earnings

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 kwi 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 kwi 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 kwi 2026, 22:14 UTC

Earnings

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 kwi 2026, 22:12 UTC

Earnings

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology Swings to Loss in 1Q>300433.SZ

15 kwi 2026, 22:07 UTC

Earnings

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 kwi 2026, 21:34 UTC

Acquisitions, Mergers, Takeovers

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 kwi 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 kwi 2026, 20:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

15 kwi 2026, 20:30 UTC

Earnings

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 kwi 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 kwi 2026, 19:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 kwi 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 kwi 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 kwi 2026, 18:58 UTC

Market Talk

Major News Events

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 kwi 2026, 18:11 UTC

Acquisitions, Mergers, Takeovers

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 kwi 2026, 17:45 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 kwi 2026, 16:58 UTC

Earnings

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 kwi 2026, 16:52 UTC

Earnings

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 kwi 2026, 16:46 UTC

Market Talk

Major News Events

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 kwi 2026, 16:37 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

48.17% upside

12 Months Forecast

Average 34.45 USD 48.17%

High 47 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

146 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.